Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT07199296RecruitingPhase 2
Study of orelabrutinib and rituximab with optional stem cell transplant for mantle cell lymphoma
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
ShanghaiAges 14 years+ - NCT07202091RecruitingPhase 2/Phase 3
Stopping or extending immunoglobulin therapy to prevent infections
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Adelaide, South AustraliaAges 18 years+ - NCT07198230Recruiting
DEB-TACE therapy for large lymphoma tumors that have returned or not responded
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
Fuzhou, FujianAges 18–75 - NCT07194980RecruitingPhase 2
A two-drug approach for relapsed or refractory CLL/SLL
This study tests a combination of an oral targeted therapy (nemtabrutinib) followed by a personalized cell therapy (lisocabtagene maraleucel, also called liso-cel) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if this sequence can improve outcomes.
Seattle, WashingtonAges 18 years+ - NCT07202078RecruitingPhase 2/Phase 3
Starting immunoglobulin for infection prevention in hematology
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Adelaide, South AustraliaAges 18 years+ - NCT04263935Recruiting
Lymphoma gene changes and what they mean for outcomes
This study looks at lymphoma’s DNA “driver gene” changes and how they relate to symptoms, lab findings, and prognosis (how the disease is expected to do over time). It may help doctors better predict outcomes for people with lymphoma based on their tumor biology.
Zhengzhou, HenanAges Any age - NCT06125483Recruiting
Cord blood transplant for cancer relapse after stem cell transplant
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
Suzhou, JiangsuAges 10–65 - NCT05407987RecruitingPhase 3
Iron infusion to improve recovery after gynecologic cancer surgery
This Phase 3 study tests whether giving a specific iron medicine before major gynecologic cancer surgery can improve recovery. It’s mainly for people with low blood counts from low iron stores before surgery.
Calgary, AlbertaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07187401RecruitingPhase 1/Phase 2
Study of a new RNA drug for PNH anemia
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
Toronto, OntarioAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07189806Recruiting
Asthma study tracking symptoms over 5 years
This study follows adults with mild, moderate, or severe asthma to better understand the condition. You'll attend regular check-ups at the clinic to monitor your lung function and symptoms over five years.
LondonAges 18 years+ - NCT07188610RecruitingPhase 2
CAR-T therapy for CD7-positive T-cell leukemia or lymphoma
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
Hefei, AnhuiAges 18 years+ - NCT07189065RecruitingPhase 2
Rocbrutinib for relapsed or refractory non-GCB DLBCL
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hefei, AnhuiAges 18 years+ - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT07191249RecruitingPhase 2
Mosunetuzumab for low-tumor-burden follicular lymphoma
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
HaifaAges 18 years+ - NCT07189117Recruiting
Study of cell metabolism in blood cancers
This study looks at how blood cancer cells use energy (metabolism) and how that affects the immune system. Researchers hope to find new ways to treat these cancers by understanding cell metabolism better.
BaselAges 18 years+ - NCT07187167RecruitingPhase 2
Lenalidomide and dexamethasone for Rosai-Dorfman disease
This trial tests a combination of two drugs, lenalidomide and dexamethasone (called the RD regimen), for people with Rosai-Dorfman disease, a rare disorder that causes immune cells to build up in the body. Researchers want to see if this treatment is safe and effective for patients who are newly diagnosed or whose disease has come back or not improved with other treatments.
BeijingAges 18–80 - NCT07190079Recruiting
New way to diagnose blood clots in the lungs using saline
This study tests a new method using a saline solution and a special imaging belt to quickly diagnose pulmonary embolism (a blood clot in the lungs) in people with acute breathing problems. If successful, it could provide a faster, safer alternative to standard CT scans.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
DalianAges 18–65 - NCT07185633RecruitingPhase 2
Study of Gecacitinib and Steroids for Acute Graft-Versus-Host Disease
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Suzhou, JiangsuAges 18 years+ - NCT07186179Recruiting
Stem cell mobilization for diamond blackfan anemia
This trial tests whether a medication can help move your own blood stem cells from your bone marrow into your bloodstream, so they can be collected. This is a first step toward possibly using those cells in a future treatment for diamond blackfan anemia.
New Hyde Park, New YorkAges 3–30 - NCT07191119Recruiting
Nerve stimulation for insomnia in childhood leukemia survivors
This study tests a small, wearable device that gently stimulates a nerve in your ear (called the vagus nerve) to help with insomnia. It's designed for adult survivors of childhood leukemia who still have trouble sleeping.
Memphis, TennesseeAges 20–50 - NCT07186959Enrolling by invitation
Weight control procedure for stubborn obesity
This trial tests a new weight management procedure for people with a higher BMI who haven't had success with other weight loss methods. It's designed for those with obesity-related health issues who are ready to lose weight.
Beijing, Beijing MunicipalityAges 18–70
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.